Urinary podocalyxin identifies a pre-albuminuric kidney injury window and stratifies 12-year diabetic kidney disease risk in youth with type 1 diabetes mellitus
- 9 May 2026
- journal article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (10) , 3569-3578
Abstract
Microalbuminuria indices may miss early diabetic kidney disease (DKD) and can regress. Urinary podocyte and tubular injury biomarkers may detect subclinical kidney injury before albuminuria. We evaluated urinary podocyte- and tubule-derived biomarkers in adolescents/young adults with type 1 diabetes mellitus (T1DM) and compared 12-year prognostic performance with albuminuria. A total of 130 participants with T1DM were screened; 109 were eligible and included in the baseline analysis, and 30 age-matched healthy controls were enrolled. Baseline urinary podocalyxin (u-PCX), nephrin (u-nephrin), and liver-type fatty acid-binding protein (u-LFABP) were measured by ELISA and indexed to creatinine; albuminuria was assessed by 24-h albumin excretion rate (u-AER) and spot albumin-to-creatinine ratio (u-ACR). Fifty-one participants were reassessed after 12 years; measurements were obtained at baseline and at the 12-year follow-up visit. Incident DKD (micro-/macroalbuminuria) was the primary outcome. Discrimination was assessed by ROC curves and Youden thresholds. At baseline, 90% had normoalbuminuria. Participants with normoalbuminuria had higher u-PCX/Cr, u-nephrin/Cr, and u-LFABP/Cr vs. controls (all p ≤ 0.001). Over 12 years, 7/51 developed DKD. Baseline u-PCX/Cr discriminated incident DKD (AUC 0.96; 95% CI 0.91-1.00): <78 ng/mgCr (NPV 100%) and ≥193 ng/mgCr had specificity 95.5%; DKD incidence across <78, 78-193 and ≥193 ng/mgCr strata was 0%, 20% and 75%, respectively (p-trend < 0.001). Baseline spot u-ACR also performed well (AUC 0.87; 95% CI 0.74-1.00). Baseline u-PCX/Cr and u-LFABP/Cr were elevated in those who developed micro-/macroalbuminuria at 12 years. Spot u-ACR remains a practical prognostic tool, while u-PCX/Cr provides complementary, actionable long-term risk cut-points requiring external validation.Keywords
Funding Information
- Manisa Celal Bayar Üniversitesi
This publication has 35 references indexed in Scilit:
- Biomarkers in diabetic nephropathy: A comprehensive review of their role in early detection and disease progression monitoringDiabetes Research and Clinical Practice, 2025
- Urinary L-FABP: A Novel Biomarker for Evaluating Diabetic Nephropathy Onset and Progression. A Narrative ReviewDiabetes Therapy, 2025
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseasesClinical and Experimental Nephrology, 2024
- Diabetic kidney disease in children and adolescents: an updatePediatric Nephrology, 2021
- Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathyClinical and Experimental Nephrology, 2017
- Update on Estimation of Kidney Function in Diabetic Kidney DiseaseCurrent Diabetes Reports, 2015
- Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxinDiabetologia, 2012
- Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and MicroalbuminuriaAn Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications CohortMicroalbuminuria Outcomes in Type 1 DiabetesArchives of internal medicine (1960), 2011
- Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideasDiabetologia, 1999